Results 311 to 320 of about 2,061,642 (403)

Giant Inguinoscrotal Hernia With Loss of Domain in a Patient With Alcoholic Liver Cirrhosis: A Case Report. [PDF]

Cureus
Olvera JA, Solis Marfil P, Guerra Bocanegra ER, Meza Hernandez CP, Gomez Martinez SA.   +4 more
europepmc   +1 more source

Genetic variants underlying precancerous conditions of hepatocellular carcinoma

International Journal of Cancer, EarlyView.
Abstract Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for 80% of cases worldwide. While chronic hepatitis B and C infections remain primary risk factors, emerging evidence highlights the increasing contributions of metabolic dysfunction‐associated steatotic liver disease (MASLD) and alcohol‐associated liver disease
Jonathan Jaime G. Guerrero, Paolo C. Encarnacion, Mark Angelo S. del Rosario, Matthew Aldren S. Ora, Jiayan Zhou, Kin Israel Notarte, Wan‐Chun Li, Ching‐Wen Chang   +7 more
wiley   +1 more source

The microbiome in cancer

iMeta, EarlyView.
This comprehensive review elucidates the transformative role of the human microbiome in cancer biology, revealing innovative mechanistic insights into the intricate tumor–microbe interactions across diverse organ systems. This work highlights the clinical and translational value of novel microbiome‐based biomarkers for early detection, prognosis, and ...
Anqi Lin, Minying Xiong, Aimin Jiang, Lihaoyun Huang, Hank Z. H. Wong, Suyin Feng, Chunyan Zhang, Yu Li, Li Chen, Hao Chi, Pengpeng Zhang, Bicheng Ye, Hengguo Zhang, Nan Zhang, Lingxuan Zhu, Weiming Mou, Junyi Shen, Kailai Li, Wentao Xu, Haoxuan Ying, Cangang Zhang, Dongqiang Zeng, Jindong Xie, Xinpei Deng, Qi Wang, Jianying Xu, Wenjie Shi, Chang Qi, Chunrun Qu, Xufeng Huang, András Hajdu, Chaoqun Li, Changmin Peng, Xuanye Cao, Guangsheng Pei, Lin Zhang, Yujia Huo, Jiabao Xu, Antonino Glaviano, Attila Gábor Szöllősi, Sicheng Bian, Zhengrui Li, Hailin Tang, Bufu Tang, Zaoqu Liu, Jian Zhang, Kai Miao, Quan Cheng, Ting Wei, Shuofeng Yuan, Peng Luo   +50 more
wiley   +1 more source

Hepatic Decompensation Associated With COVID-19 in a Patient With Alcoholic Liver Cirrhosis: A Case Report. [PDF]

Cureus
Gengo M.
europepmc   +1 more source

Mitochondrial dysfunction: Related diseases, influencing factors, and detection

Interdisciplinary Medicine, EarlyView.
Mitochondrial dysfunction is implicated in the pathogenesis of numerous diseases, including neurological disorders, cancers, and cardiovascular conditions, through mechanisms such as mitochondrial DNA mutations, dysregulation of mitochondrial network dynamics, and impaired mitophagy.
Zhaojin Li, Shiyu Li, Wanying Chen, Ziyu Zhang, Chun Pan, Peng Lei, Cheng Cheng, Junyou Zhu, Hanxiao Sun, Zhenning Dai   +9 more
wiley   +1 more source

Plasma Beta-Hydroxybutyrate and All-Cause Mortality in Patients with Liver Cirrhosis. [PDF]

Biomedicines
Chvatal-Medina M, Li Y, Trillos-Almanza MC, Post A, Connelly MA, Moshage H, Bakker SJL, Meijer VE, Blokzijl H, Dullaart RPF, TransplantLines Investigators.   +10 more
europepmc   +1 more source

In Vitro Assessment of Drug‐Induced Liver Injury Using Three‐Dimensional Cultured HepaSH Cells Derived From Chimeric Mouse Model With Humanized Liver

Journal of Applied Toxicology, EarlyView.
ABSTRACT Drug‐induced liver injury (DILI) is a serious adverse event and a common cause of postmarketing drug withdrawal. Despite nonclinical assessments of DILI risk, which are predominantly conducted in experimental animals, DILI remains a frequent adverse event, highlighting the need to improve nonclinical assessments.
Xingming Liu, Yuichiro Higuchi, Yuta Sakamoto, Shota Yanagida, Shotaro Uehara, Hiroshi Suemizu, Yasunari Kanda, Hiroyuki Kawagishi   +7 more
wiley   +1 more source

Management of Dental Extraction in Liver Cirrhosis: A Case Report. [PDF]

Cureus
Elnaem IS, Aloudah EM, Essa HA, Alenzi LH, Alghris AM.   +4 more
europepmc   +1 more source

Pharmacokinetics and Safety of Fezolinetant in Women with Hepatic or Renal Impairment

The Journal of Clinical Pharmacology, EarlyView.
Abstract The neurokinin 3 receptor antagonist fezolinetant is an approved treatment for vasomotor symptoms due to menopause. The impacts of hepatic and renal impairment on the pharmacokinetics and safety of a single oral dose of fezolinetant 30 mg were investigated in two independent studies.
Megumi Iwai, Xuegong Wang, Melanie Patton, Lauren Benner, Nakyo Heo, Jace C. Nielsen, Anna Spence, Thomas C. Marbury, Jiayin Huang   +8 more
wiley   +1 more source